Literature DB >> 16238041

Transpupillary thermotherapy in the treatment of central serous chorioretinopathy.

Song-Yang Wei1, Chung-May Yang.   

Abstract

A 40-year-old man had persistent central serous chorioretinopathy at the foveal region for 20 months. The pretreatment best-corrected visual acuity was 0.3. The leaking point was close to the fovea, making the use of argon laser photocoagulation treatment unsafe. Transpupillary thermal therapy with diode laser (power setting = 120 mW, spot size = 1.2 mm, and duration = 60 seconds) was performed to cover the whole detached area. The subretinal fluid decreased 1 week later. Fluorescein angiography 2 months later revealed neither further leakage nor any subretinal fluid. After 3 months of follow-up, best-corrected visual acuity improved to 0.4. Transpupillary thermal therapy may be a useful alternative for the treatment of chronic, persistent central serous chorioretinopathy at the fovea.

Entities:  

Mesh:

Year:  2005        PMID: 16238041

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  4 in total

1.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

Review 2.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

3.  Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy.

Authors:  V Mathur; Jks Parihar; R Maggon; S K Mishra
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Effect of Intravitreal Injection of Bevacizumab on Acute Central Serous Chorioretinopathy Patients Who Visited Feiz Hospital during 2014-2015 Period.

Authors:  Mohamad Reza Akhlaghi; Cobra Nasrollahi; Seyed Mohamad Namgar; Farzan Kianersi; Ali Reza Dehghani; Reza Arefpour
Journal:  Adv Biomed Res       Date:  2017-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.